Sentiment from Key Opinion Leaders regarding ADAURA Trial presented at #ASCO23
Total Impressions 910,582
Key Opinion Leader Sentiment Analysis of ADAURA Trial
| Doctor Name |
Sentiment |
Comment |
|
Stephen V Liu, MD |
POSITIVE
|
Highlight of the #IULungSymposium is getting to hear Dr. Larry Einhorn discuss the field. Poses critical questions for the field. One of the great speakers in thoracic oncology. #LCSM https://t.co/BrpOk63tLy |
|
Nathan A. Pennell MD, PhD, FASCO |
POSITIVE
|
Thanks to @VivekSubbiah for giving @JackWestMD and I a chance to channel our debates into surprising consensus! #LCSM Lessons from ADAURA: Can we improve on a positive trial? - West and Pennell - Cancer https://t.co/3h47aR03gd |
|
Jonathan Spicer MD PhD |
POSITIVE
|
#ALINA, #ADAURA and #KN671 were all smiles today @myESMO #ESMO23! Love these guys! https://t.co/094rK9iW1B |
|
Charu Aggarwal, MD, MPH, FASCO |
POSITIVE
|
@christine_lovly @Alexmenter @ASCO @OncoAlert @OncBrothers @JackWestMD I see that using the word “cure” makes oncologists uncomfortable. The curves above show that we are undeniably improving survival. https://t.co/xWdKhfa03s |
|
Christine Lovly, MD, PhD |
POSITIVE
|
@Alexmenter @CharuAggarwalMD @ASCO @OncoAlert @OncBrothers Agree! I am very enthusiastic about the ADAURA data. But can we truly say “cure” with the available data? @JackWestMD |
|
Balazs Halmos, MD |
POSITIVE
|
#ASCO23 ADAURAble results! How it started How it is going 👇 👇 https://t.co/WuvwSG6qn6 |
|
H. Jack West, MD |
NEUTRAL
|
🚨That also doesn't factor in that the patients directed to adjuvant chemo almost certainly had higher risk disease, while those who didn't were enriched for more favorable disease features. Know that if you don't recommend adjuvant chemo, you're undertreating. https://t.co/73QGsmEhzd |
|
Jeff Ryckman, MD |
NEGATIVE
|
@MassimoDiMaio75 Love how the response is that "data suggest that the greatest overall survival benefit is achieved with the use of adjuvant osimertinib, as supported by the results of the ADAURA and FLAURA trials" ...as if there were a trial of salvage vs. adjuvant osimertinib?? The prevailing… https://t.co/vgdEtbAKbo |
|
Vinay Prasad MD MPH |
NEGATIVE
|
#adaura has dozens and dozens of authors. Fda onc hundreds of employees. Not a single one of them fought for the control arm patients. Now control on patients have to litigate. I don't disagree, but it is amazing. #asco23 https://t.co/Qna3mYVfiW |
|
Vladmir C. Cordeiro de Lima, MD, PhD |
NEGATIVE
|
@JackWestMD 👍When you're about to present a potentially paradigm-shifting study, you better make all effort to leave no room for questioning. In this particular case: no PET / brain RM before osi initiation, adjv chemo at invest discretion, OS as 2nd endpoint, no mandatory crossover at PD. |
|
H. Jack West, MD |
NEGATIVE
|
Helpful background. But AZ promoted osi as clear optimal 1L SOC for relapsed/adv EGFRm+ NSCLC since 2017 presentation of ADAURA, & osi was longstanding 1L SOC in US & much of ROW long before 4/2020. IMO, disngenuous to say that while not yet offering to pts w/relapse in ctrl arm. https://t.co/MavabLw2mU |